Shanghai Yizhong Pharmaceutical Co.Ltd(688091) : Paclitaxel micelle, the core product, is included in the Clinical guidelines of Chinese Medical Association for Lung Cancer

Shanghai Yizhong Pharmaceutical Co.Ltd(688091) June 19 announcement, the core product of Paclitaxel Polymer micelle for Injection (hereinafter referred to as “Paclitaxel micelle”) is included in the Clinical guidelines of Chinese Medical Association for Lung Cancer (2022 Edition), the Combination of Platinum is recommended for the first – line Treatment of Non – squamous Cell Carcinoma Driven Gene negative patients (recommended evidence of class 1), and SQU Paclitaxel micelle es el primer producto de Paclitaxel micelle no comercializado en el país y en el extranjero aprobado por la administración estatal de drogas y pertenece a la clase 2.2 de nuevos medicamentos.